ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

IMC Immuron Limited

0.086
-0.004 (-4.44%)
14 Jun 2024 - Closed
Delayed by 20 minutes
Share Name Share Symbol Market Type
Immuron Limited ASX:IMC Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.004 -4.44% 0.086 0.086 0.09 0.086 0.086 0.086 48,955 09:50:00

Immuron Gets FDA Approval to Proceed With Travelan Evaluation

23/12/2022 11:50am

Dow Jones News


Immuron (ASX:IMC)
Historical Stock Chart


From Jun 2022 to Jun 2024

Click Here for more Immuron Charts.

By Chris Wack

 

Immuron Ltd. said Friday that it has received approval from the U.S. Food and Drug Administration to proceed with the clinical evaluation of Travelan.

The company said the Investigational New Drug application to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli strain H10407 is now active.

As a result of this approval, the company will proceed with its planned clinical trial in the U.S. The safety and protective efficacy of Travelan will be tested using a controlled human infection-model clinical trial design.

Immuron is the sponsor of the IND, and the clinical study will be conducted by the Contract Research Organization Pharmaron CPC Inc. at its FDA inspected clinical research facility located in Baltimore.

The Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan in a controlled human infection model using the enterotoxigenic Escherichia coli strain H10407. Recruitment is planned to be initiated in the first half of 2023, with headline results from the clinical trial expected to be reported by year end 2023.

Immuron shares were up 55% to $2.48 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

December 23, 2022 06:35 ET (11:35 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Immuron Chart

1 Year Immuron Chart

1 Month Immuron Chart

1 Month Immuron Chart

Your Recent History

Delayed Upgrade Clock